Stone Pharmaceutical Group (01093): The phase III clinical trial of SYS 6043 for the treatment of platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer has officially started at the first center in China.

Zhtng Cijng APP News, Shyo Jtun (01093) released an announcement that the group has officially started a randomized, multicenter, open-label Phase III clinical trial in China for evaluating its developed SYS 6043 (B7-H3-ADC) compared to the chemotherapy selected by researchers for the treatment of platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants.